Sees Q2 Revenue of $60M-$80M, Estimate at $74.7M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 04 2026
0mins
Should l Buy MED?
Sees Q2 revenue $60M-$80M, one estimate $74.7M
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MED?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MED
About MED
Medifast, Inc. is a health and wellness company. The Company is engaged in offering habit-based and coach-guided lifestyle solution, OPTAVIA. It sells a variety of weight loss, weight management and healthy living products all based on its proprietary formulas under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories. Its product line includes approximately 74 consumable options, including, but not limited to, bars, cereal, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. Its OPTAVIA ASCEND mini meals deliver nutrition that gives clients’ bodies what they need to - whether losing weight on a GLP-1 medication or in weight management mode. Its OPTAVIA Fuelings contain approximately 24 vitamins and minerals, high quality, complete protein, and no colors, flavors or sweeteners from artificial sources.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medifast Q1 Earnings Beat Expectations, Shares Surge 18%
- Significant Stock Surge: Medifast shares jumped nearly 18% on Tuesday, rising from $10.63 to approximately $12.63, significantly outperforming the S&P 500's 15.13% one-day gain, reflecting market optimism about the company's future potential.
- Weak Financial Performance: Despite Q1 revenue falling 34.3% year-over-year to $76 million, primarily due to a 44.9% drop in active coaches to 14,000, the average revenue per active coach increased by 19.2% to $5,432, indicating improved productivity among the remaining coaches.
- Effective Cost Control: The company's gross profit declined 38.6% to $51.8 million in Q1, yet SG&A expenses fell by 35.6%, demonstrating the effectiveness of its cost-cutting measures, with expectations of generating over $30 million in future savings.
- Positive Future Outlook: Although the net loss widened to $2.1 million (or $0.19 per share), the company ended the quarter with $168.9 million in cash and no debt, with management stating that they have realigned their cost structure effectively and plan to launch a new metabolic health system in July, which could further fuel stock price increases.
See More
Medifast Q1 2026 Earnings Call Insights and Outlook
- Initial Revenue Growth: Medifast reported Q1 2026 revenue of $76 million, a 34.3% year-over-year decline, yet marked the first sequential revenue growth in three years, indicating early signs of business stabilization that could lay the groundwork for future market recovery.
- Declining Coach Numbers: The number of active earning coaches fell to approximately 14,000, down 44.9% year-over-year; however, the average revenue per coach increased by 19.2% to $5,432, suggesting progress in enhancing coach productivity despite the overall decline.
- Cost Structure Optimization: The company anticipates generating over $30 million in future savings through a realignment of its cost structure, which not only helps address market realities but may also facilitate a return to profitability starting in Q4 2026, thereby strengthening financial health.
- New Product Line Launch: Medifast plans to unveil a new comprehensive metabolic system at its coach convention in July, with management reiterating that this product launch will be crucial for restoring profitability, expected to drive sustained earnings growth into 2027 and beyond.
See More
Medifast (MED) to Announce Q1 Earnings on May 4th
- Earnings Announcement Schedule: Medifast (MED) is set to release its Q1 2023 earnings report on May 4th after market close, with consensus EPS estimate at -$0.52 and revenue estimate at $69.2 million, reflecting a 40.2% year-over-year decline.
- Historical Performance: Over the past two years, Medifast has exceeded EPS estimates 88% of the time and revenue estimates 88% of the time, indicating a degree of stability in its financial performance despite current challenges.
- Expectation Adjustments: In the last three months, there have been no upward revisions to EPS estimates, with one downward revision, while revenue estimates also saw no upward revisions and one downward revision, suggesting market caution regarding future performance.
- Future Revenue Targets: Medifast has outlined a revenue target of $270 million to $300 million for 2026, indicating the company's commitment to driving execution amid CEO transition and a focus on metabolic health for long-term growth.
See More
Medifast Earnings Preview: Revenue Expectations Decline
- Revenue Decline: Medifast reported $75.1 million in revenue last quarter, a 36.9% year-over-year drop, with full-year revenue and EPS guidance significantly missing analysts' expectations, indicating ongoing market challenges for the company.
- Market Expectations: This quarter, the market anticipates a 40.2% year-over-year revenue decline for Medifast, a further deceleration from the 33.8% decrease recorded in the same quarter last year, reflecting a trend of weakening consumer demand.
- Analyst Confidence: Despite Medifast missing Wall Street's revenue estimates multiple times over the past two years, analysts covering the company have reaffirmed their estimates in the last 30 days, suggesting a cautiously optimistic outlook for the company's future performance.
- Competitive Comparison: In the consumer staples sector, Estée Lauder and Vita Coco reported year-over-year growth of 4.6% and 37.3%, respectively, highlighting strong performances from industry peers and increasing pressure on Medifast to improve its results.
See More
Insider Buying at Cardinal Infrastructure and Medifast
- CDNL Insider Purchase: Ivy Zelman, a director at Cardinal Infrastructure Group, bought 6,921 shares of CDNL at $36.33 each, totaling $251,440, with a current gain of about 6.9%, indicating strong market confidence.
- Stock Performance: CDNL is up approximately 4.2% on Monday, reflecting investor optimism about the company's prospects, with Zelman's purchase further bolstering market sentiment.
- MED Insider Purchase: Medifast CEO Daniel R. Chard purchased 17,678 shares at $10.11 each on Wednesday, totaling $178,725, demonstrating management's confidence in the company's future.
- Historical Trading Comparison: Chard previously bought 5,003 shares at $13.13 each over the past year, indicating a sustained investment commitment to Medifast despite the current stock price decline.
See More
Medifast Nominates New Director Candidates for 2026 Meeting
- Board Nominations: Medifast has announced the nomination of Parsa Kiai and Jeff Rose as independent director candidates for the 2026 Annual Meeting, reflecting a Cooperation Agreement with Steamboat Capital, which owns over 5% of the company's shares, aimed at enhancing board independence and expertise.
- Management Changes: The Board has decided that Jeffrey Brown and Michael Hoer will not seek reelection, with current CEO Dan Chard set to step down on June 1, 2026, and Nicholas Johnson expected to succeed him, indicating a strategic shift in leadership to align with future growth.
- Strategic Cooperation Agreement: Under the Cooperation Agreement with Steamboat Capital, both parties have agreed to certain voting and standstill provisions until the 2027 Annual Meeting, aiming to drive Medifast's continued development and profitability, thereby enhancing shareholder returns.
- Market Potential Recognition: Parsa Kiai, Managing Partner at Steamboat Capital, noted that the market significantly undervalues Medifast's financial and intrinsic assets, emphasizing the company's unique platform in metabolic health and its long-term growth potential, suggesting that future collaboration will drive sustainable profitability.
See More
Medifast Q1 Earnings Beat Expectations, Shares Surge 18%
- Significant Stock Surge: Medifast shares jumped nearly 18% on Tuesday, rising from $10.63 to approximately $12.63, significantly outperforming the S&P 500's 15.13% one-day gain, reflecting market optimism about the company's future potential.
- Weak Financial Performance: Despite Q1 revenue falling 34.3% year-over-year to $76 million, primarily due to a 44.9% drop in active coaches to 14,000, the average revenue per active coach increased by 19.2% to $5,432, indicating improved productivity among the remaining coaches.
- Effective Cost Control: The company's gross profit declined 38.6% to $51.8 million in Q1, yet SG&A expenses fell by 35.6%, demonstrating the effectiveness of its cost-cutting measures, with expectations of generating over $30 million in future savings.
- Positive Future Outlook: Although the net loss widened to $2.1 million (or $0.19 per share), the company ended the quarter with $168.9 million in cash and no debt, with management stating that they have realigned their cost structure effectively and plan to launch a new metabolic health system in July, which could further fuel stock price increases.
See More
Medifast Q1 2026 Earnings Call Insights and Outlook
- Initial Revenue Growth: Medifast reported Q1 2026 revenue of $76 million, a 34.3% year-over-year decline, yet marked the first sequential revenue growth in three years, indicating early signs of business stabilization that could lay the groundwork for future market recovery.
- Declining Coach Numbers: The number of active earning coaches fell to approximately 14,000, down 44.9% year-over-year; however, the average revenue per coach increased by 19.2% to $5,432, suggesting progress in enhancing coach productivity despite the overall decline.
- Cost Structure Optimization: The company anticipates generating over $30 million in future savings through a realignment of its cost structure, which not only helps address market realities but may also facilitate a return to profitability starting in Q4 2026, thereby strengthening financial health.
- New Product Line Launch: Medifast plans to unveil a new comprehensive metabolic system at its coach convention in July, with management reiterating that this product launch will be crucial for restoring profitability, expected to drive sustained earnings growth into 2027 and beyond.
See More
Medifast (MED) to Announce Q1 Earnings on May 4th
- Earnings Announcement Schedule: Medifast (MED) is set to release its Q1 2023 earnings report on May 4th after market close, with consensus EPS estimate at -$0.52 and revenue estimate at $69.2 million, reflecting a 40.2% year-over-year decline.
- Historical Performance: Over the past two years, Medifast has exceeded EPS estimates 88% of the time and revenue estimates 88% of the time, indicating a degree of stability in its financial performance despite current challenges.
- Expectation Adjustments: In the last three months, there have been no upward revisions to EPS estimates, with one downward revision, while revenue estimates also saw no upward revisions and one downward revision, suggesting market caution regarding future performance.
- Future Revenue Targets: Medifast has outlined a revenue target of $270 million to $300 million for 2026, indicating the company's commitment to driving execution amid CEO transition and a focus on metabolic health for long-term growth.
See More
Medifast Earnings Preview: Revenue Expectations Decline
- Revenue Decline: Medifast reported $75.1 million in revenue last quarter, a 36.9% year-over-year drop, with full-year revenue and EPS guidance significantly missing analysts' expectations, indicating ongoing market challenges for the company.
- Market Expectations: This quarter, the market anticipates a 40.2% year-over-year revenue decline for Medifast, a further deceleration from the 33.8% decrease recorded in the same quarter last year, reflecting a trend of weakening consumer demand.
- Analyst Confidence: Despite Medifast missing Wall Street's revenue estimates multiple times over the past two years, analysts covering the company have reaffirmed their estimates in the last 30 days, suggesting a cautiously optimistic outlook for the company's future performance.
- Competitive Comparison: In the consumer staples sector, Estée Lauder and Vita Coco reported year-over-year growth of 4.6% and 37.3%, respectively, highlighting strong performances from industry peers and increasing pressure on Medifast to improve its results.
See More
Insider Buying at Cardinal Infrastructure and Medifast
- CDNL Insider Purchase: Ivy Zelman, a director at Cardinal Infrastructure Group, bought 6,921 shares of CDNL at $36.33 each, totaling $251,440, with a current gain of about 6.9%, indicating strong market confidence.
- Stock Performance: CDNL is up approximately 4.2% on Monday, reflecting investor optimism about the company's prospects, with Zelman's purchase further bolstering market sentiment.
- MED Insider Purchase: Medifast CEO Daniel R. Chard purchased 17,678 shares at $10.11 each on Wednesday, totaling $178,725, demonstrating management's confidence in the company's future.
- Historical Trading Comparison: Chard previously bought 5,003 shares at $13.13 each over the past year, indicating a sustained investment commitment to Medifast despite the current stock price decline.
See More
Medifast Nominates New Director Candidates for 2026 Meeting
- Board Nominations: Medifast has announced the nomination of Parsa Kiai and Jeff Rose as independent director candidates for the 2026 Annual Meeting, reflecting a Cooperation Agreement with Steamboat Capital, which owns over 5% of the company's shares, aimed at enhancing board independence and expertise.
- Management Changes: The Board has decided that Jeffrey Brown and Michael Hoer will not seek reelection, with current CEO Dan Chard set to step down on June 1, 2026, and Nicholas Johnson expected to succeed him, indicating a strategic shift in leadership to align with future growth.
- Strategic Cooperation Agreement: Under the Cooperation Agreement with Steamboat Capital, both parties have agreed to certain voting and standstill provisions until the 2027 Annual Meeting, aiming to drive Medifast's continued development and profitability, thereby enhancing shareholder returns.
- Market Potential Recognition: Parsa Kiai, Managing Partner at Steamboat Capital, noted that the market significantly undervalues Medifast's financial and intrinsic assets, emphasizing the company's unique platform in metabolic health and its long-term growth potential, suggesting that future collaboration will drive sustainable profitability.
See More
